Literature DB >> 22474186

Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.

Purnima K Wagh1, Glendon M Zinser, Jerilyn K Gray, Archana Shrestha, Susan E Waltz.   

Abstract

The Ron receptor tyrosine kinase (macrophage stimulating 1 receptor) is overexpressed in approximately 50% of human breast cancers. Transgenic mice overexpressing Ron in the mammary epithelium [mouse mammary tumor virus driven (MMTV)-Ron expressing mice] develop mammary tumors that exhibit up-regulation of β-catenin and β-catenin target genes. β-Catenin has been shown to be a mediator of mammary tumorigenesis in various breast cancer models, including downstream of Ron. However, the in vivo impact of a conditional loss of β-catenin downstream of Ron receptor overexpression on the onset, growth, turnover, and metastasis of mammary tumors has not been addressed. To determine the significance of β-catenin in the context of Ron overexpression, we conditionally deleted β-catenin in mammary epithelial cells of MMTV-Ron mice. Conditional deletion of β-catenin in the mammary epithelium, through the use of whey acidic protein (WAP)-Cre transgenic mice, significantly delayed the onset of mammary hyperplastic nodules, the presence of palpable mammary tumors, and ultimately decreased liver metastasis. β-Catenin loss in this model was also associated with decreased expression of cyclin D1. In total, these studies support an important role for β-catenin downstream of Ron receptor signaling during the development of mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474186      PMCID: PMC3359604          DOI: 10.1210/en.2011-1543

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  30 in total

Review 1.  Management of local recurrence of breast cancer.

Authors:  Alexandra M Easson; David R McCready
Journal:  Expert Rev Anticancer Ther       Date:  2004-04       Impact factor: 4.512

2.  Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.

Authors:  Alessandro Sgambato; Mario Migaldi; Beatrice Faraglia; Graziella De Aloysio; Paolo Ferrari; Raffaele Ardito; Carmela De Gaetani; Giovanni Capelli; Achille Cittadini; Gian Paolo Trentini
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.

Authors:  B E Peace; M J Hughes; S J Degen; S E Waltz
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

4.  Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Authors:  A Danilkovitch-Miagkova; A Miagkov; A Skeel; N Nakaigawa; B Zbar; E J Leonard
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

5.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.

Authors:  S Y Lin; W Xia; J C Wang; K Y Kwong; B Spohn; Y Wen; R G Pestell; M C Hung
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 6.  BRCA1-associated tumorigenesis: what have we learned from knockout mice?

Authors:  S G Brodie; C X Deng
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

7.  Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells.

Authors:  Yi Li; Bryan Welm; Katrina Podsypanina; Shixia Huang; Mario Chamorro; Xiaomei Zhang; Tracey Rowlands; Mikala Egeblad; Pam Cowin; Zena Werb; Lee K Tan; Jeffrey M Rosen; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

Review 8.  Beta-catenin and Tcfs in mammary development and cancer.

Authors:  Sarah Hatsell; Tracey Rowlands; Minoti Hiremath; Pamela Cowin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

9.  β-Catenin is required for Ron receptor-induced mammary tumorigenesis.

Authors:  P K Wagh; J K Gray; G M Zinser; J Vasiliauskas; L James; S P Monga; S E Waltz
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

10.  Beta-catenin: a transforming actor on many stages.

Authors:  Keiko Miyoshi; Lothar Hennighausen
Journal:  Breast Cancer Res       Date:  2002-12-20       Impact factor: 6.466

View more
  9 in total

Review 1.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 2.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

3.  Fatty acid synthase is required for mammary gland development and milk production during lactation.

Authors:  Janel Suburu; Lihong Shi; Jiansheng Wu; Shihua Wang; Michael Samuel; Michael J Thomas; Nancy D Kock; Guangyu Yang; Steven Kridel; Yong Q Chen
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-03-25       Impact factor: 4.310

4.  Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.

Authors:  Wies van Roosmalen; Sylvia E Le Dévédec; Ofra Golani; Marcel Smid; Irina Pulyakhina; Annemieke M Timmermans; Maxime P Look; Di Zi; Chantal Pont; Marjo de Graauw; Suha Naffar-Abu-Amara; Catherine Kirsanova; Gabriella Rustici; Peter A C 't Hoen; John W M Martens; John A Foekens; Benjamin Geiger; Bob van de Water
Journal:  J Clin Invest       Date:  2015-03-16       Impact factor: 14.808

5.  Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.

Authors:  Abby L Johnson; Glendon M Zinser; Susan E Waltz
Journal:  Oncotarget       Date:  2015-06-30

6.  HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.

Authors:  Nancy M Benight; Purnima K Wagh; Glendon M Zinser; Belinda E Peace; William D Stuart; Juozas Vasiliauskas; Peterson Pathrose; Sandra L Starnes; Susan E Waltz
Journal:  Oncotarget       Date:  2015-07-10

7.  HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.

Authors:  Sasha J Ruiz-Torres; Nancy M Benight; Rebekah A Karns; Elyse E Lower; Jun-Lin Guan; Susan E Waltz
Journal:  Oncotarget       Date:  2017-07-22

8.  NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.

Authors:  Sara Vicente-Muñoz; Brian G Hunt; Taylor E Lange; Susanne I Wells; Susan E Waltz
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

9.  mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential.

Authors:  Najme Faham; Ling Zhao; Alana L Welm
Journal:  NPJ Breast Cancer       Date:  2018-11-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.